Indonesia

Sanofi’s Dengue Vaccine Promising But Offers Incomplete Protection Sanofi’s Dengue Vaccine Promising But Offers Incomplete Protection
  • July 11th, 2014
  • A late-stage clinical trial has shown that Sanofi’s dengue vaccine reduces dengue hemorrhagic fever by 89 percent but does not protect against serotype 2.

» Read More...
Featured Research »
Sanofi’s Dengue Vaccine Promising But Offers Incomplete Protection

Sanofi’s Dengue Vaccine Promising But Offers Incomplete Protection

A late-stage clinical trial has shown that Sanofi’s dengue vaccine reduces dengue hemorrhagic fever by 89 percent but does not protect against serotype 2.

Health & Medicine »
Heart Failure Hits Asians Earlier

Heart Failure Hits Asians Earlier

A study of 8,000 heart failure patients shows that heart failure occurs at a much younger age for Asians, who develop the disease a good decade before people in Western countries.

Academia »
Five Female Chemists Win TWAS Awards

Five Female Chemists Win TWAS Awards

Five chemists from Indonesia, Jamaica, Nigeria, Uzbekistan and Yemen have won at the second Elsevier Foundation Awards for Early Career Women Scientists in the Developing World.

Tech & Pharma »
Sanofi Pasteur Concludes Phase III Trial For Dengue Vaccine

Sanofi Pasteur Concludes Phase III Trial For Dengue Vaccine

The Phase III trial, which enrolled more than 10,000 children in Asia, showed that vaccination led to a 56 percent reduction in dengue cases.

Editorials »
Indonesia’s Forest Loss Linked To Oil Palm Industry

Indonesia’s Forest Loss Linked To Oil Palm Industry

Satellite images show that Indonesia has lost six million hectares of primary forest from 2000-2012, due in part to expanding oil palm plantations.